FDA approves first continuous glucose monitoring system for adults not requiring blood sample calibration
FDA Press Announcements Oct 11, 2017
The U.S. Food and Drug Administration approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip (often referred to as a ÂfingerstickÂ).
The system reduces the need for fingerstick testing by using a small sensor wire inserted below the skinÂs surface that continuously measures and monitors glucose levels. Users can determine glucose levels by waving a dedicated, mobile reader above the sensor wire to determine if glucose levels are too high (hyperglycemia) or too low (hypoglycemia), and how glucose levels are changing. It is intended for use in people 18 years of age and older with diabetes; after a 12-hour start-up period, it can be worn for up to 10 days.
ÂThe FDA is always interested in new technologies that can help make the care of people living with chronic conditions, such as diabetes, easier and more manageable, said Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health and deputy director of new product evaluation in the FDAÂs Center for Devices and Radiological Health. ÂThis system allows people with diabetes to avoid the additional step of fingerstick calibration, which can sometimes be painful, but still provides necessary information for treating their diabetes - with a wave of the mobile reader.Â
The FDA evaluated data from a clinical study of individuals aged 18 and older with diabetes, and reviewed the deviceÂs performance by comparing readings obtained by the FreeStyle Libre Glucose Monitoring System to those obtained by an established laboratory method used for analysis of blood glucose.
Risks associated with use of the system may include hypoglycemia or hyperglycemia in cases where information provided by the device is inaccurate and used to make treatment decisions, as well as mild skin irritations around the insertion site. It does not provide real-time alerts or alarms in the absence of a user-initiated action; for example, it cannot alert users to low blood glucose levels while they are asleep.
The FreeStyle Libre Flash Glucose Monitoring System is manufactured by Abbott Diabetes Care Inc.
Go to Original
The system reduces the need for fingerstick testing by using a small sensor wire inserted below the skinÂs surface that continuously measures and monitors glucose levels. Users can determine glucose levels by waving a dedicated, mobile reader above the sensor wire to determine if glucose levels are too high (hyperglycemia) or too low (hypoglycemia), and how glucose levels are changing. It is intended for use in people 18 years of age and older with diabetes; after a 12-hour start-up period, it can be worn for up to 10 days.
ÂThe FDA is always interested in new technologies that can help make the care of people living with chronic conditions, such as diabetes, easier and more manageable, said Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health and deputy director of new product evaluation in the FDAÂs Center for Devices and Radiological Health. ÂThis system allows people with diabetes to avoid the additional step of fingerstick calibration, which can sometimes be painful, but still provides necessary information for treating their diabetes - with a wave of the mobile reader.Â
The FDA evaluated data from a clinical study of individuals aged 18 and older with diabetes, and reviewed the deviceÂs performance by comparing readings obtained by the FreeStyle Libre Glucose Monitoring System to those obtained by an established laboratory method used for analysis of blood glucose.
Risks associated with use of the system may include hypoglycemia or hyperglycemia in cases where information provided by the device is inaccurate and used to make treatment decisions, as well as mild skin irritations around the insertion site. It does not provide real-time alerts or alarms in the absence of a user-initiated action; for example, it cannot alert users to low blood glucose levels while they are asleep.
The FreeStyle Libre Flash Glucose Monitoring System is manufactured by Abbott Diabetes Care Inc.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries